Ipsen Stock Under Pressure: Weekly Decline of 6.8% and Threatened Supports
The French biopharmaceutical company is slightly in the red in early afternoon trading, moving against a well-oriented CAC 40. The stock struggles to halt a slide that began in mid-May, as technical indicators deteriorate and several clinical catalysts are expected in the coming weeks.
The Stock Breaks its Support at €151.80 and Slips Below its Short-Term Moving Averages
Ipsen's stock loses 0.13% at €151.60 during the session, after breaking its support at €151.80 in the morning. The decline remains limited for the day, but is part of a clearly deteriorating dynamic: -6.82% over a week and -9.22% over a month. The stock is now trading below its MM20 (€162.14) and MM50 (€161.34), with a gap of more than 6% in both cases. Only the cushion compared to the MM200 (€136.66) remains comfortable, at nearly 11%, illustrating a short-term movement that contrasts with a still solid annual performance of 46.19%.
The RSI at 36 reflects the selling exhaustion of recent sessions, without yet signaling a return to a clear oversold zone.
In the detail of the SBF 120, the red is concentrated on a few biotech and satellite stocks (Abivax, Eutelsat, SES), while session gains are seen in tech and collective catering. Ipsen remains apart from these two poles, neither driving nor lagging, in a broadly rising index by 0.54%.
Clinical Pipeline in Focus, Following the Confirmation of Iqirvo's Profile
The fundamental context remains active. During the EASL congress on May 28, the group presented three analyses confirming the efficacy of Iqirvo on fatigue and the reduction of alkaline phosphatases in primary biliary cholangitis. This publication echoed the opportunities identified during the first quarter 2026 results (published on May 28), which pointed to improvements in 67% of treated patients.
In parallel, the laboratory demonstrated the non-inferiority of Dysport compared to Botox in the DIRECTION study on upper limb spasticity, presented at the ISPRM. On Friday, the group also launched its fifth employee savings plan, deployed in 36 countries based on a reference price of €130.96.
Regarding risks reported at the May 28 accounts publication, the group recalls the exposure to generic competition and regulatory uncertainties on its treatments in development. Looking ahead, the resistance at €172.90 remains distant for now. The market is now monitoring the behavior of the stock around the former support at €151.80, which has become a short-term technical pivot zone.
